The selective oestrogen receptor modulator, bazedoxifene, mimics the neuroprotective effect of 17-oestradiol in diabetic ischaemic stroke by modulating oestrogen receptor expression and the MAPK/ERK1/2 signalling pathway.
Autores de IIS La Fe
Grupos
Abstract
Because neuroprotection in stroke should be revisited in the era of recanalisation, the present study analysed the potential neuroprotective effect of the selective oestrogen receptor modulator, bazedoxifene acetate (BZA), in an animal model of diabetic ischaemic stroke that mimics thrombectomy combined with adjuvant administration of a putative neuroprotectant. Four weeks after induction of diabetes (40mgkg -1 streptozotocin, i.p.), male Wistar rats were subjected to transient middle cerebral artery occlusion (intraluminal thread technique, 60minutes) and assigned to one of three groups treated with either: vehicle, BZA (3mgkg -1 day -1 , i.p.) or 17-oestradiol (E 2 ) (100gkg -1 day -1 , i.p.). At 24hours post-ischaemia-reperfusion, brain damage (neurofunctional score, infarct size and apoptosis), expression of oestrogen receptors (ER)a, ER and G protein-coupled oestrogen receptor), and activity of the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK)1/2 and phosphoinositide 3-kinase/Akt pathways were analysed. At 24hours after the ischaemic insult, both BZA- and E 2 -treated animals showed lower brain damage in terms of improved neurofunctional condition, decreased infarct size and decreased apoptotic cell death. Ischaemia-reperfusion induced a significant decrease in ERa and ER expression without affecting that of G protein-coupled oestrogen receptor, whereas BZA and E 2 reversed such a decrease. The ischaemic insult up-regulated the activity of both the MAPK/ERK1/2 and phosphoinositide 3-kinase/Akt pathways; BZA and E 2 attenuated the increased activity of the ERK1/2 pathway, without affecting that of the Akt pathway. The results of the present study lend further support to the consideration of BZA as an effective and safer alternative overcoming the drawbacks of E 2 with respect to improving diabetic ischaemic stroke outcome after successful reperfusion.
Datos de la publicación
- ISSN/ISSNe:
- 0953-8194, 1365-2826
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.1111/jne.12751
- Factor de Impacto:
- 1,083 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
JOURNAL OF NEUROENDOCRINOLOGY Blackwell Publishing Inc.
Citas Recibidas en Web of Science: 10
Documentos
- No hay documentos
Filiaciones
Keywords
- 17ß-oestradiol, apoptosis, bazedoxifene, diabetes, ischaemic stroke, selective oestrogen receptor modulators
Proyectos asociados
INVESTIGACION EN RED DE LAS ENFERMEDADES NEUROLOGICAS
Investigador Principal: JUAN JESÚS VÍLCHEZ PADILLA
C03/06 . INSTITUTO DE SALUD CARLOS III . 2003
RED DE INVESTIGACION (RENEVAS)
Investigador Principal: ENRIQUE ALBORCH DOMÍNGUEZ
RD06/0026/0006 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA (FIDIS); FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2006
RED DE INNOVACION EN TECNOLOGIAS MEDICAS Y SANITARIAS - RED ITEMAS
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
RD09/0077/00156 . INSTITUTO DE SALUD CARLOS III . 2010
MICROCLUSTERS-CALIDAD, SEGURIDAD Y FUNCIONALIDAD DE ALIMENTOS
Investigador Principal: JOSÉ LUIS MULLOR SANJOSÉ
2011_0171_VLC/CAMPUS_MCI_MULLOR_SALOM . 2011
INFLUENCIA DE LA DIABETES SOBRE LAS VIAS DE SEÑALIZACION DE LOS RECEPTORES ESTROGENICOS CEREBRALES EN EL ICTUS ISQUEMICO AGUDO EXPERIMENTAL: IMPLICACIONES TERAPEUTICAS
Investigador Principal: GERMÁN TORREGROSA BERNABÉ
PI12/00145 . INSTITUTO DE SALUD CARLOS III . 2013
ENFERMEDADES VASCULARES CEREBRALES (ICTUS)
Investigador Principal: JUAN BAUTISTA SALOM SANVALERO
RD12/0014/0004 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013
NANOMATERIALES INTELIGENTES, SONDAS Y DISPOSITIVOS PARA EL DESARROLLO INTEGRADO DE NUEVAS HERRAMIENTAS APLICADAS AL CAMPO BIOMÉDICO
Investigador Principal: JUAN BAUTISTA SALOM SANVALERO
MAT2015-64139-C4-1-R . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD . 2016
RED DE ENFERMEDADES VASCULARES CEREBRALES. INVICTUS PLUS.
Investigador Principal: JUAN BAUTISTA SALOM SANVALERO
RD16/0019/0008 . INSTITUTO DE SALUD CARLOS III . 2017
SMARRTS-II- MARCADORES DE ANGIOGENESIS Y REPARACIÓN DURANTE TERAPIA REHABILITADORA TRAS EL ICTUS: ESTUDIO CLÍNICO MULTICÉNTRICO.
Investigador Principal: ANNA ROSELL NOVEL
PI16/00981 . 2016
ESTUDIO DE DABIGATRÁN EN LA FASE TEMPRANA DEL ICTUS. ESTUDIO DE NUEVOS MARCADORES DE NEUROIMAGEN Y DE BIOMARCADORES. (ESTUDIO SEDMAN)
Investigador Principal: AIDA LAGO MARTÍN
JKB-DAB-2016-01 . 2018
Cita
Burguete MC,Jover T,López MA,Aliena A,Jorques M,Torregrosa G,Alborch E,Castelló M,Salom JB. The selective oestrogen receptor modulator, bazedoxifene, mimics the neuroprotective effect of 17-oestradiol in diabetic ischaemic stroke by modulating oestrogen receptor expression and the MAPK/ERK1/2 signalling pathway. J. Neuroendocrinol. 2019. 31. (8):e12751. IF:2,886. (3).